Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-5.06	-2.6	-1.81	-1.05	-2.15
Depreciation & Amortization	0.16	0.16	0.16	0.16	0.1
Other Amortization	-	0.15	0.06	0.41	0.14
Stock-Based Compensation	0.44	0.22	-	-	0.3
Other Operating Activities	1.49	0.1	0.91	-	-
Change in Accounts Payable	-0.33	0.4	0.77	0.13	1.19
Change in Other Net Operating Assets	-0.86	-2.39	-0.01	-	-
Operating Cash Flow	-4.16	-3.96	0.08	-0.35	-0.41
Cash Acquisitions	-	-	-	-	-0.11
Investing Cash Flow	-	-	-	-	-0.11
Short-Term Debt Issued	-	0.14	-	-	-
Long-Term Debt Issued	-	-	-	0.93	0.35
Total Debt Issued	3.6	0.14	-	0.93	0.35
Short-Term Debt Repaid	-	-0.14	-	-0.04	-0.02
Total Debt Repaid	-0.14	-0.14	-	-0.04	-0.02
Net Debt Issued (Repaid)	3.46	-	-	0.89	0.33
Issuance of Common Stock	-	5.52	-	-	0.25
Other Financing Activities	3.06	-0.39	-0.43	-0.17	-
Financing Cash Flow	6.52	5.13	-0.43	0.72	0.58
Net Cash Flow	2.36	1.18	-0.34	0.36	0.06
Cash Interest Paid	0	0	-	-	-
Levered Free Cash Flow	-3.62	-5.35	0.76	0.01	-
Unlevered Free Cash Flow	-3.62	-5.38	0.77	-0.12	-
Change in Working Capital	-1.19	-1.98	0.76	0.13	1.19

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q